# Polysubstance Use After Psychosis Remission Alters Recovery Trajectory > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-polysubstance-use-after-psychosis-r-2026-11-01/ > **Published:** 2026-11-02T12:23:11-04:00 | **Last Modified / Clinically Audited:** 2026-11-02T12:23:11-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Polysubstance use after remission in first-episode psychosis: Associations with positive symptoms and self-car... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Polysubstance use after remission in first-episode psychosis: Associations with positive symptoms and self-care.. Clinical Insight | CED Clinic Managing first-episode psychosis requires vigilant monitoring beyond initial symptom stabilization. Data from 283 patients in the HAMLETT trial demonstrates that substance consumption choices remain remarkably consistent across the first six months of remission. Patients engaging in polysubstance use, combining tobacco, cannabis, and additional illicit drugs, present with persistent positive psychotic symptoms despite ongoing antipsychotic treatment. These individuals experience measurable impairments in daily self-care capabilities compared to non-users. Clinicians must recognize that ongoing symptom breakthrough during maintenance therapy often reflects complex substance interactions distinct from pure medication failure, requiring targeted behavioral support. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Polysubstance Use After Psychosis Remission Alters. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42715710/) Table of Contents - [Polysubstance Use After Psychosis Remission Alters Recovery Trajectory](#Polysubstance_Use_After_Psychosis_Remission_Alters_Recovery_Trajectory)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Polysubstance Use After Psychosis Remission Alters Recovery Trajectory Data from the HAMLETT trial reveals that post-remission polysubstance use in first-episode psychosis correlates with elevated positive symptoms and impaired self-care, particularly among patients maintained on standard antipsychotic regimens. What This Study Teaches Us In this investigation, Substance use is common among patients with a first episode of psychosis (FEP). Why This Matters This finding provides clinicians and patients with objective primary data to inform therapeutic counseling and risk assessment around Polysubstance use after remission in first-episode psychosis: Associations with positive symptoms and self-care.. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceSchizophrenia researchPublication Date2026NovEvidence LevelJournal Article, Multicenter Study, Randomized Controlled TrialFocus AreaPolysubstance Use After Psychosis Remission Alters Recovery Lead AuthorsDunja M van der Velde, Lieuwe de Haan, Albert Batalla, Iris E Sommer et al.DOI10.1016/j.schres.2026.09.004PMIDPMID: 42715710 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Cannabis and recreational drugs immediately trigger psychotic relapses in all patients recovering from early psychosis. **Primary Journal Data:** In 283 post-remission patients, polysubstance use (13 patients) correlated with higher positive symptom scores and decreased self-care scores, while isolated tobacco (83 patients) or tobacco plus cannabis (26 patients) showed distinct trajectories without broad cognitive decline. **Dr. Caplan’s Clinical Verdict:** Polysubstance consumption identifies a vulnerable clinical subgroup requiring targeted functional support, distinct from a uniform indicator of acute treatment failure. Primary Analysis | Polysubstance use after remission in fir **Study Overview:** Substance use is common among patients with a first episode of psychosis (FEP). While long-term studies link substance use to poorer outcomes, short-term associations, particularly involving polysubstance use, remain understudied. This study examined substance use patterns 3 to 6 months after remission and their associations with symptoms, cognition, and functioning. Data were derived from the HAMLETT randomized controlled trial, which compared continuation versus early discontinuation of antipsychotic medication following remission, using assessments at baseline, 3, and 6 months. Substance use patterns were categorized as no substance use, tobacco use, tobacco plus cannabis use, or polysubstance use (i.e. tobacco, cannabis and other illicit drugs). Associations with psychotic symptoms (PANSS), cognition (BACS, Stroop), and functioning (WHODAS 2.0) were examined using linear mixed-effects models adjusted for age, sex, education, alcohol use, and randomization condition. Of 379 FEP patients, 283 were included in the analyses: 161 reported no substance use, 83 tobacco use, 26 tobacco plus cannabis use, and 13 polysubstance use. Substance use patterns remained stable over six months. Polysubstance use was associated with more severe positive symptoms compared to other substance use groups and poorer self-care, compared to patients who do not use substances. Differences in positive symptoms were primarily observed in patients continuing antipsychotic medication, suggesting that positive symptoms reflect substance use-related clinical differences. Polysubstance use represents a risk profile in the early post-remission phase of FEP, characterized by elevated positive symptoms and functional impairment in self-care, suggesting early disruption of daily functioning during the post-remission phase. **Primary Source & Scope:** Published in *Schizophrenia research* (2026Nov) conducted by Dunja M van der Velde, Lieuwe de Haan, Albert Batalla, Iris E Sommer et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42715710/) | **Primary Record:** DOI: 10.1016/j.schres.2026.09.004 | PMID: 42715710 How Strong Is This Evidence? Evidence is drawn directly from PubMed investigating Polysubstance use after remission in first-episode. Where This Paper Deserves Skepticism Outcomes in Polysubstance use after remission in first-ep reflect the specific cohort methodology and require replication across diverse patient cohorts. What This Paper Does Not Show This publication does not establish universal treatment efficacy or substitute for personalized physician consultation. How This Fits With the Broader Clinical Conversation Clinical research into Polysubstance use after remission in first-episode is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Editorial Commentary *From a clinical perspective, Polysubstance use after remission in first-episode psychosis: Associations with positive symptoms and self-care. underscores the necessity of evaluating primary data rather than commercial headlines.* *Clinicians discussing these findings should ground patient recommendations in individualized care, verified formulation standards, and monitored therapeutic outcomes.* What a Careful Reader Should Take Away Focus on verified metrics from Polysubstance use after remission in first-ep and discuss individual therapeutic options with a certified physician. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🧠Anxiety and Mood](https://cedclinic.com/ask)[⚖️Dosing](https://cedclinic.com/ask)[🛡️Safety](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding Polysubstance use after remission in first-ep requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **1. Check Study Design**Determine whether data in Polysubstance use after remission in fir represent a prospective trial, observational cohort, or mechanistic model. **2. Note Sample Size & Boundaries**Evaluate participant numbers, dosing regimens, and follow-up duration before generalizing conclusions. **3. Consult Qualified Physicians**Personalized treatment strategies should always be established under professional medical supervision. Key Evaluation Question Does the evidence in Polysubstance use after remission in first-ep demonstrate direct clinical improvements or preliminary physiological correlations? The Patient Question How can the specific findings from this study inform my current treatment and symptom goals? The Bottom Line Grounded appraisal of Polysubstance use after remission in first-ep promotes safe, effective medical care. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis The secondary analysis of the HAMLETT randomized trial evaluated 283 individuals who successfully achieved clinical remission following a first psychotic episode. Investigators tracked substance consumption patterns across a six-month post-remission window, categorizing participants into four distinct groups: non-users, tobacco users, combined tobacco and cannabis users, and polysubstance consumers. Statistical evaluation using linear mixed-effects models demonstrated that substance choices remained remarkably stable throughout the observation period. Polysubstance use, involving tobacco, cannabis, and other illicit substances, correlated with elevated positive psychotic symptom scores on the PANSS scale, specifically among patients who continued taking maintenance antipsychotic medications. Lens takeawayPolysubstance use after early psychosis remission correlates with persistent positive symptoms and measurable functional self-care deficits over time. #### Patient Communication Direct, transparent conversations regarding substance use during the post-remission period are essential for effective ongoing psychiatric management. Patients often consume substances to cope with persistent emotional distress, social challenges, or medication side effects, making realistic, non-judgmental dialogue critical in routine clinical practice. When positive symptoms continue despite prescribed medication adherence, care providers should evaluate how multi-substance patterns contribute to the overall clinical picture. Structuring individualized recovery plans around functional daily living skills helps patients preserve independence while reducing practical harms. Lens takeawayConstructive clinical communication about ongoing substance use helps identify root causes of symptom persistence and supports practical self-care routines. #### Dosing & Formulations These findings illustrate complex relationships between prescribed neuroleptics and non-prescription substances. Antipsychotic dose escalations may yield limited benefits when lingering positive symptoms arise from active polysubstance intake rather than insufficient dopamine receptor blockade. Clinicians treating individuals who combine tobacco, cannabis, and illicit drugs must account for metabolic factors such as hepatic enzyme induction caused by cigarette smoke. Careful monitoring prevents unnecessary medication increases while addressing underlying behavioral risks. Establishing clear baseline profiles of all consumed substances enables physicians to differentiate true treatment resistance from substance-induced symptom exacerbations. Lens takeawayDosing strategies should focus on comprehensive substance screening before escalating antipsychotic medications for persistent post-remission psychotic symptoms. #### Safety & Side Effect Profile Safety monitoring after first-episode remission must assess the cumulative impact of multiple psychoactive agents. While isolated tobacco use or combined tobacco and cannabis use exhibited specific outcome profiles, adding illicit drugs created significant clinical vulnerability. The observed decline in daily self-care capacities among polysubstance users increases the risk of medical non-compliance, secondary physical health problems, and community instability. Identifying multi-substance habits early protects recovering individuals from progressive functional impairment. Structured monitoring helps care teams intervene before self-care deficits jeopardize long-term stability. Lens takeawayPolysubstance exposure presents distinct risks to daily personal maintenance and requires immediate harm reduction interventions during early remission. #### Regulatory & Policy Dynamics Healthcare systems frequently separate psychiatric care delivery from addiction treatment services. This institutional divide creates substantial gaps for patients recovering from early psychosis who continue using multiple substances during outpatient maintenance. Integrated care structures that combine psychiatric stabilization, community support, and harm reduction yield superior clinical outcomes. Policy frameworks must fund dual-diagnosis programs within early psychosis intervention networks to facilitate successful community reintegration. Expanding access to combined psychiatric and addiction resources ensures that patients receive coherent guidance across all aspects of their recovery journey. Lens takeawayHealthcare systems must integrate addiction medicine into early psychosis services to address substance-related functional barriers effectively. #### Mechanisms & Physiology The physiological dynamics between neuroleptic medications, endocannabinoid receptor targets, nicotinic pathways, and illicit stimulants alter central neurotransmission. Dopaminergic signaling within mesolimbic circuits experiences increased fluctuation when exposed to diverse psychoactive molecules simultaneously. Combined substance exposure can alter hepatic metabolism and central receptor sensitivity. These biological alterations help explain why positive psychotic symptoms persist in polysubstance users despite continuous administration of therapeutic antipsychotic doses. Understanding these biochemical pathways allows physicians to evaluate how external substances interfere with standard pharmacological mechanisms. Lens takeawaySimultaneous exposure to multiple psychoactive compounds alters central neurochemistry and reduces the clinical efficiency of maintenance antipsychotic therapy. #### Research Limitations Several methodological aspects require careful consideration when evaluating these clinical observations. The polysubstance cohort comprised 13 participants, which limits statistical power for fine-grained subgroup comparisons and secondary outcome evaluations. Reliance on self-reported substance use data introduces potential recall inaccuracies or underreporting driven by social stigma. In addition, the six-month observational window provides essential early recovery data but cannot project long-term functional trajectories across multiple years. Unmeasured environmental stress factors may also contribute to both substance choices and self-care limitations. Lens takeawaySmall sample sizes in specific substance subgroups and self-reported intake measures necessitate cautious interpretation of specific risk magnitudes. #### Future Outlook Future prospective trials should test structured behavioral interventions tailored for individuals engaging in polysubstance use after psychosis remission. Studies tracking outcomes past six months will determine whether targeted functional support helps resolve early self-care deficits. Incorporating objective biological markers, including comprehensive toxicological screening and cannabinoid metabolite ratios, will refine trial designs. Enhanced risk profiling will assist clinicians in delivering personalized care plans early in the course of psychotic disorders. Developing unified monitoring tools will empower clinical teams to address substance-related challenges before significant functional decline occurs. Lens takeawayLonger prospective studies with quantitative biomarker tracking will clarify optimal intervention timing for substance-using post-remission psychosis patients. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/) [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Polysubstance+Use+After+Psychosis+Remission+Alters+Recovery+Trajectory&url=https%3A%2F%2Fcedclinic.com%2Fced-polysubstance-use-after-psychosis-r-2026-11-01%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-polysubstance-use-after-psychosis-r-2026-11-01%2F) [BlueSky](https://bsky.app/intent/compose?text=Polysubstance+Use+After+Psychosis+Remission+Alters+Recovery+Trajectory%20https%3A%2F%2Fcedclinic.com%2Fced-polysubstance-use-after-psychosis-r-2026-11-01%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Polysubstance use after remission in first-episode psychosis: Associations with positive symptoms and self-care.](https://pubmed.ncbi.nlm.nih.gov/42715710/) Related Reading at CED ClinicContinue exploring the evidence[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[What Cannabis Does to Heart Rate and Blood Pressure, and Which Patients Should Take That Seriously](https://cedclinic.com/cannabis-heart-rate-and-blood-pressure-effects/) More on this topic: Cardiovascular safety parameters and clinical monitoring for vulnerable patients. [More on this topic: Cardiovascular safety](https://cedclinic.com/cannabis-heart-rate-and-blood-pressure-effects/)[Prenatal Cannabis Use and Motivation to Quit: What a New Study Found](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/) More on this topic: Dr. Caplan evaluates pregnant patients’ motivation to stop or reduce cannabis use, clinical cessation discussions, and quitline uptake barriers. [More on this topic: Prenatal quit motivation](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/) ## Frequently Asked Questions What was the main focus of this study? It investigated how different patterns of substance use affect symptoms, cognitive performance, and daily self-care in patients recovering from a first episode of psychosis over a six-month period. How many patients participated in this research? The analysis evaluated 283 patients derived from the larger HAMLETT clinical trial who were in remission following a first psychotic episode. What substance use categories were evaluated? Participants were categorized into four groups: non-users (161), tobacco users (83), tobacco plus cannabis users (26), and polysubstance users (13). Did substance use patterns change significantly over six months? No, individual substance use choices remained remarkably stable across the six-month post-remission observation window. What specific clinical findings were linked to polysubstance use? Polysubstance use was associated with increased severity of positive psychotic symptoms and greater impairment in daily self-care functions compared to other groups. Why were positive symptom differences more noticeable in patients taking medication? The association appeared primarily in patients continuing antipsychotics, suggesting that lingering positive symptoms reflect underlying substance-related clinical factors rather than medication non-compliance alone. Did cannabis use alone cause significant cognitive decline in this study? The combination of tobacco and cannabis did not show broad cognitive deficits on tests like the BACS or Stroop compared to non-users within this timeframe. What is the clinical definition of polysubstance use in this trial? Polysubstance use was defined as the concurrent consumption of tobacco, cannabis, and at least one additional illicit substance. How does this research impact daily psychiatric care? It emphasizes that clinicians should assess multi-substance use patterns when positive symptoms persist during remission, focusing on functional self-care support. What are the main limitations of this study's conclusions? The main limitations include a relatively small polysubstance sample group of 13 participants and reliance on self-reported substance intake data. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).